Physician profile
Mark Crawshaw
NPI 1265009559
$609.79
in general payments reported to CMS, 2019-2025
13 companies · $511 in 2025
The $511 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.89 · 2022: $46.66 · 2024: $34.47 · 2025: $511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $545.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $545.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $164.43 | 2025 | |
| Amgen INC. | $63.32 | 2024-2025 | Otezla |
| Incyte Corporation | $55.34 | 2025 | Opzelura, Opzelura |
| Organon LLC | $53.27 | 2025 | Vtama, Hadlima |
| Leo Pharma INC. | $50.71 | 2025 | Adbry, Anzupgo |
| Si-Bone, INC. | $46.66 | 2022 | |
| Janssen Biotech, INC. | $43.46 | 2025 | Tremfya |
| Genzyme Corporation | $33.97 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $28.77 | 2025 | Libtayo |
| Biocon Biologics INC | $22.17 | 2025 | Yesintek |
| Medtronic, INC. | $17.89 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.33 | 2025 | Spevigo |
| Arcutis Biotherapeutics, INC. | $14.47 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Crawshaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.